InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,186.00
(
-0.15%
)
Dow Jones
39,127.80
(
0.00%
)
Brent Oil
84.89
(
0.50%
)
Bitcoin
61,159.90
(
0.57%
)
Post# of 4764
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biophud

Send PM Follow Ignore
Followers 0
Posts 394
Boards Moderated 0
Alias Born 08/12/2006

biophud

Re: jbog post# 4539

Sunday, 03/02/2008 10:41:44 AM

Sunday, March 02, 2008 10:41:44 AM

Post# of 4764
Jbog--IMCL has an impressive pipeline. Given the number of clinical trials it seems to me that IMCL will need help in development/clinical trials. How do you think IMCL will proceed with development (go it alone vs collaborations). I know IMCL has mentioned potential collaborations for non-oncology indications. What molecule(s) does it make sense for IMCL to develop without a partner? The questions I have are when will IMCL partner, at what stage phase of development, and with whom. I would think that the anti-IGFR antibody would be a good candidate to partner due to the multiple competing molecules in development. On the other hand IMCL has NCI support in the development of this molecule.

Comments appreciated,

biophud
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up